Filtered By:
Condition: Diabetes
Cancer: Ovarian Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 37 results found since Jan 2013.
PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis
Hum Reprod Update. 2023 Jun 23:dmad015. doi: 10.1093/humupd/dmad015. Online ahead of print.ABSTRACTBACKGROUND: Current knowledge about the consequences of PCOS during the late reproductive years and after menopause is limited.OBJECTIVE AND RATIONALE: We performed a systematic review and meta-analysis of data on the pathophysiology, clinical manifestations, diagnosis, prognosis, and treatment of women ≥45 years of age-peri- or postmenopausal-with PCOS.SEARCH METHODS: Studies published up to 15 April 2023, identified by Entrez-PubMed, EMBASE, and Scopus online facilities, were considered. We included cross-sectional or pro...
Source: Cancer Control - June 24, 2023 Category: Cancer & Oncology Authors: Mercedes Mill án-de-Meer Manuel Luque-Ram írez L ía Nattero-Chávez H éctor F Escobar-Morreale Source Type: research
Impact of Comorbidities on Lung Cancer Screening Evaluation
CONCLUSION: Patient and procedure-level factors may alter the benefits of lung cancer screening. Data concerning individual risk factors and high-risk complications should therefore be incorporated into diagnostic algorithms to optimize clinical benefit and minimize harm. Further study and validation of the risk factors identified herein are warranted.PMID:35641376 | DOI:10.1016/j.cllc.2022.03.012
Source: Clinical Prostate Cancer - May 31, 2022 Category: Cancer & Oncology Authors: Eric M Robinson Benjamin Y Liu Keith Sigel Chung Yin Juan Wisnivesky Minal S Kale Source Type: research
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Mendelian randomization analyses for PCOS: evidence, opportunities, and challenges
Trends Genet. 2022 Jan 27:S0168-9525(22)00005-1. doi: 10.1016/j.tig.2022.01.005. Online ahead of print.ABSTRACTIdentifying etiological risk factors is significant for preventing and treating patients with polycystic ovary syndrome (PCOS). Through genetic variation, Mendelian randomization (MR) assesses causal associations between PCOS risk and related exposure factors. This emerging technology has provided evidence of causal associations of anti-Müllerian hormone (AMH) levels, sex hormone-binding globulin (SHBG) levels, menopause age, adiposity, insulin resistance (IR), depression, breast cancer, ovarian cancer, obsessive...
Source: Trends in Genetics : TIG - January 31, 2022 Category: Genetics & Stem Cells Authors: Congying Wang Wei Wu Haiyan Yang Zhenhong Ye Yue Zhao Jun Liu Liangshan Mu Source Type: research
Causes and Consequences of Polycystic Ovary Syndrome: Insights from Mendelian Randomization
CONCLUSIONS: The accumulation of genome-wide association studies in PCOS has enabled multiple MR analyses identifying factors that may cause PCOS or be caused by PCOS. This knowledge will be critical to future development of measures to prevent PCOS in girls at risk as well as prevent complications in those who have PCOS.PMID:34669940 | DOI:10.1210/clinem/dgab757
Source: The Journal of Clinical Endocrinology and Metabolism - October 20, 2021 Category: Endocrinology Authors: Tiantian Zhu Mark O Goodarzi Source Type: research
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
CDKN2B-AS1: An indispensable long non-coding RNA in multiple diseases.
CONCLUSIONS: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases.
PMID: 32767927 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 4, 2020 Category: Drugs & Pharmacology Authors: Song C, Qi Y, Zhang J, Guo C, Yuan C Tags: Curr Pharm Des Source Type: research
